Apimeds Pharmaceuticals US (APUS) Revenue (2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Revenue came in at $282989.0 in Q2 2026.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Revenue (2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Revenue for 1 consecutive years, with $282989.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | 282,989.00 |